Larance B - Search Results

1

Opioid agonist treatment for pharmaceutical opioid dependent people.

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Nielsen S, et al. Among authors: larance b. Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Cochrane Database Syst Rev. 2016. PMID: 27157143 Updated. Review.

2

Drug dependence and associated risks among female street-based sex workers in the greater Sydney area, Australia.

Roxburgh A, Degenhardt L, Copeland J, Larance B. Roxburgh A, et al. Among authors: larance b. Subst Use Misuse. 2008 Jul;43(8-9):1202-17. doi: 10.1080/10826080801914410. Subst Use Misuse. 2008. PMID: 18649239

3

Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.

Larance B, Degenhardt L, Copeland J, Dillon P. Larance B, et al. Drug Alcohol Rev. 2008 Nov;27(6):679-86. doi: 10.1080/09595230802392568. Drug Alcohol Rev. 2008. PMID: 18825549

4

Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.

Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP. Degenhardt L, et al. Med J Aust. 2009 Aug 3;191(3):161-5. doi: 10.5694/j.1326-5377.2009.tb02729.x. Med J Aust. 2009. PMID: 19645647

5

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L. Horyniak D, et al. Among authors: larance b. Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004. Epub 2010 Nov 27. Int J Drug Policy. 2011. PMID: 21112758

6

Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.

Larance B, Degenhardt L, O'Brien S, Lintzeris N, Winstock A, Mattick RP, Bell J, Ali R. Larance B, et al. Drug Alcohol Rev. 2011 Nov;30(6):613-20. doi: 10.1111/j.1465-3362.2010.00274.x. Epub 2011 Jan 5. Drug Alcohol Rev. 2011. PMID: 21355939

7

Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. Larance B, et al. Drug Alcohol Rev. 2011 May;30(3):236-45. doi: 10.1111/j.1465-3362.2010.00283.x. Drug Alcohol Rev. 2011. PMID: 21545553 Review.

8

The availability, diversion and injection of pharmaceutical opioids in South Asia.

Larance B, Ambekar A, Azim T, Murthy P, Panda S, Degenhardt L, Mathers B. Larance B, et al. Drug Alcohol Rev. 2011 May;30(3):246-54. doi: 10.1111/j.1465-3362.2011.00304.x. Drug Alcohol Rev. 2011. PMID: 21545554 Review.

9

Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, Mattick R, Ali R, Horyniak D. Larance B, et al. Drug Alcohol Depend. 2011 Nov 1;118(2-3):265-73. doi: 10.1016/j.drugalcdep.2011.04.002. Epub 2011 May 12. Drug Alcohol Depend. 2011. PMID: 21565452

10

Prescription of opioid analgesics and related harms in Australia.

Roxburgh A, Bruno R, Larance B, Burns L. Roxburgh A, et al. Among authors: larance b. Med J Aust. 2011 Sep 5;195(5):280-4. doi: 10.5694/mja10.11450. Med J Aust. 2011. PMID: 21895598

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

111 results

Search Page